Abstract: A cosmetic product for temporarily reshaping keratin-containing fibers, in particular human hair, containing, in a cosmetic carrier, in relation to its total weight, a) from about 0.01 to about 10 wt. % of at least one (meth)acrylamidopropyltrimethylammonium salt homo- or copolymer; b) from about 0.1 to about 10 wt. % of at least one non-ionic, anionic and/or amphoteric film-forming polymer, use thereof, and method using this product.

Abstract: A hair fixative composition comprising a film forming polymer that is prepared from monomers comprising (a) 10-30% by weight of one or more copolymerizable comonomers selected from the group consisting of N-alkyl (meth)acrylamide wherein the alkyl group thereof contains from 2 to 12 carbon atoms, wherein for at least one of said copolymerizable comonomers the alkyl group contains from 5 to 12 carbon atoms; (b) 14-21% by weight of copolymerizable comonomers comprising acrylic acid and optionally one or more acidic copolymerizable comonomers selected from the group consisting of methacrylic acid, crotonic acid, itaconic acid, maleic acid, fumaric acid, and the (C1-C4)alkyl half esters of maleic and fumaric acids; and (c) 40-76% by weight two or more copolymerizable comonomers selected from the group consisting of (C1-C12)alkyl(meth)acrylates, wherein at least one of said two or more copolymerizable comonomers is a (C1-C2)alkyl(meth)acrylate; said film forming polymer being optionally completely or partially neu

Abstract: A cosmetic agent for the temporary styling of keratinic fibers, in particular human hair, containing, in a cosmetic support, with respect to its total weight, a) from about 0.1% to about 2.0% by weight of chitosan or chitosan derivative b) from about 0.5% to about 7.0% by weight of polyimide, its use and a method employing this agent.

Abstract: A cosmetic agent for the temporary styling of keratinic fibers, in particular human hair, containing, in a cosmetic support, with respect to its total weight, a) from about 0.05% to about 5.0% by weight of at least one (meth)acrylamidopropyltrimethylammonium salt homo- or copolymer; b) from about 0.5% to about 10% by weight of polyimide, the uses thereof and a method employing this agent.

Abstract: This invention is directed to a composition for treating and preventing hair loss in male and female, for regrowth stimulation of hair in male and female, for replenishing the previously colored hair in male and female, and for stimulation of healthy and strong finger nail growth, wherein the composition is a nutrition supplement.

Abstract: Described herein are systems and methods for transmucosal delivery of active agents. In some embodiments, a system may comprise one or more mucoadhesive devices configured for release of an active agent.

Abstract: The wound treatment therapy deactivates pathogenic microorganisms within the wound environment without disrupting the cell walls. The wound treatment therapy of this invention combines the application of stabilized hypochlorous acid compound with the application of a hydrophobic wound dressing. The application of hypochlorous acid provides the initial anti-microbial agent, which disrupts and eradicates biofilm, as well as, deactivates the harmful pathogenic organisms within the wound environment. The application of the hydrophobic wound dressing, which is designed to bind harmful hydrophobic microorganisms and toxins, provides a mechanical vehicle for physically removing deactivated hydrophobic microorganisms form the wound environment with each dressing change.

Abstract: Embodiments of various aspects described herein relate to methods and compositions for injecting and/or delivering high viscosity and/or high concentration active agent solutions. In some embodiments, the methods and compositions described herein can be used for subcutaneous administration.

Abstract: The invention provides artificial tear compositions, artificial tear-gel compositions, contact lens storage compositions, contact lens treatment compositions, ophthalmological drug vehicle compositions and topical drug vehicle compositions comprising one or more nonionic surfactants with one or more non-Newtonian viscosity enhancing excipients and one or more of a polyol and or an electrolyte and methods of their use.

Abstract: Oral liquid colchicine formulations are described herein. Methods of using the oral liquid colchicine formulations are also provided.

Abstract: This disclosure relates to polymersomes comprising a crosslinked polymer and their use as drug delivery vehicles. Specifically, polymersomes comprising a polymer of Formula I: wherein each R is independently C1-6 alkyl; and n is an integer between 1 and 50.

Abstract: The present invention is directed to pediatric formulation of (R)-N-[-1-(1-naphthyl)-ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine hydrochloride (hereinafter referred to as Cinacalcet HC1) and method of administering the same.

Abstract: Provided is a hydroxyalkyl alkyl cellulose exhibiting good flowability and high compressibility. More specifically, there are provided a hydroxyalkyl alkyl cellulose having a volume-based average particle size, determined by dry laser diffractometry, of more than 100 ?m and not more than 150 ?m; and after dividing all particles into fine particles, spherical particles and fibrous particles by a dynamic image analysis, a volume fraction of the fibrous particles relative to all of the particles of more than 40% and not more than 50%, and a volume fraction of the fine particles relative to all of the particles of less than 2.0%; a solid preparation including the hydroxyalkyl alkyl cellulose; and others.

Abstract: A solid pharmaceutical oral composition for twice daily administration is provided. The composition includes from about 0.3 mg to about 0.6 mg in total of methylergonovine or a pharmaceutically acceptable salt thereof. The composition is used for treating a subject having a methylergonovine responsive condition such as migraine, refractory migraine, uterine atony, uterine haemorrhage, subinvolution of the uterus, and uterine haemorrhage in the second stage of labor.

Abstract: The present invention relates to a capsule composition of raloxifene comprising multiparticulates comprising a) a core comprising raloxifene, and b) a taste-masking coating present in amount of from about 0.5% to about 50% w/w based on the core weight.

Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.

Abstract: Formulations containing pH-sensitive nanoparticles for the enteric delivery of therapeutic agents are provided. The nanoparticles include a pH-sensitive polymer that protects the therapeutic agent against degradation in the stomach and allows it to be released in the small intestine or colon. The nanoparticle formulation is particularly effective at protecting sensitive biotherapeutic agents from degradation when administered orally, and makes it possible to avoid administration of such agents by injection. Also provided are methods for producing the formulations, as well as methods of treating diseases employing the formulations.

Abstract: Particles comprising an opioid receptor antagonist as well as methods of their use and methods of their preparation are provided herein. Such particles may be used for treating and preventing opioid-induced side effects in patients, and may be provided to chronic opioid users as well.

Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures comprise at least a first major cannabinoid, at least a first minor cannabinoid, and optionally at least a first selected terpene. Also provided are methods of making the complex mixtures; pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Lewy Body Dementia, or Huntington's disease.

Abstract: The invention provides compositions and methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation. The method comprises administering an effective amount of curcuminoid containing composition to a human male on an as-needed basis shortly before sexual activity to delay ejaculation.

Abstract: Provided are methods of inhibiting aggregation of amyloid-beta (A?) or accumulation of aggregated A? using certain guanylhydrazone compounds. Also provided are methods of treating or preventing an amyloid-related disease in a mammal, methods of treating a subject having Alzheimer's disease, methods of treating a subject at risk for Alzheimer's disease, methods of inhibiting aggregation or accumulation of a synuclein, methods of treating a subject having a disease at least partially mediated by synuclein, methods of treating a subject at risk for a disease at least partially mediated by synuclein, and methods of inhibiting aggregation or accumulation of a protein involved in a conformational disease, using the guanylhydrazone compounds.

Abstract: The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to enhance or promote lipolysis, increase adipocyte fat oxidation, induce adipocyte and muscle mitochondrial biogenesis, increase energy expenditure, decrease total body weight and increase body fat loss.

Abstract: Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, compounds, compounds may be utilized for treating infection by Toxoplasma gondii and toxoplasmosis and for treating infection by Plasmodium falciparum and malaria. The compounds disclosed herein are observed to selectively inactivate Toxoplasma gondii ornithine aminotransferase (TgOAT) relative to human OAT and relative to human ?-aminobutyric aminotransferase (GABA-AT).

Abstract: A mineral-vitamin complex for osteoporosis includes at least 92 mass % of the mineral-vitamin complex of amino acids and Krebs cycle acids and/or Krebs cycle acid salts, wherein the amino acids include glycine of between 1% and 80% of the mineral-vitamin complex, and wherein the Krebs cycle acids and/or Krebs cycle acid salts are up to 5 mass % of the mineral-vitamin complex; and valine, leucine and isoleucine such that a mass ratio of glycine to a sum of valine+leucine+isoleucine is in a range of 10-1000. Optionally, the valine, leucine and isoleucine are derived from dry milk, any stable dry product derived from milk and/or a mix thereof. Optionally, the following compounds are used as a source of Krebs cycle acid salts: Y-Me-Y.nH2O, where Me—divalent metal, from Ca, Mg, Zn group, Y—anion of an acid participating in Krebs cycle, and n=0-12.

Abstract: Ingesting an agent containing cystine or a salt thereof, as an active ingredient, is effective for improving exercise-induced gastrointestinal disorder, providing an improvement effect equal to or better than that by the conventional technology on exercise-induced gastrointestinal disorders including exercise-induced decline in gastrointestinal tract barrier function.

Abstract: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C1-C10 monocarboxylic acids and C2-C22 polycarboxylic acids.

Abstract: Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such, as found in Alzheimer's and similar conditions. These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: A method for treating bladder cancer including the steps of administering an isothiocyanate functional surfactant to an area affected by bladder cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

Abstract: Methods comprising administration of and kits comprising at least one compound of formula (I); and at least one additional anti-cancer therapy chosen from panitumumab, cetuximab, capecitabine, CAPDX, regorafenib, and FOLFOX.

Abstract: The present invention relates to a composition for the prevention and treatment of pancreatitis comprising a naphthoquinone-based compound, a pharmaceutically acceptable salt, a prodrug, a solvate, or an isomer of the same. Particularly, the naphthoquinone-based compounds ?-lapachone and dunnione can reduce the pancreatic weight/body weight ratio, which is increased by pancreatitis; reduce the increased activities of digestive enzymes (amylase and lipase); reduce the expressions of cytokines (IL-1? (interleukin-1?) and MCP-1); reduce or inhibit the inflammation, edema, and cell necrosis of the pancreatic tissues; and inhibit the lung damage caused by pancreatitis. Therefore, the naphthoquinone-based compound, the pharmaceutically acceptable salt, the pro-drug, the solvate, or the isomer thereof can be effectively used as a composition for the prevention and treatment of pancreatitis.

Abstract: An embodiment of the invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected, from among the group of Apigenin, Cannflavin. A. Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaempferol, Luteolin, Myricetin, Orientin, Isoorientin (Homoorientin), Quercetin (+)-Taxifolin, Vitexin, and Isovitexin, or their synthases, for the prevention and treatment of certain cancers that can be treated by therapeutically targeting oncogenic factors including kinases, sirtuins, bromodomains, matrix metalloproteinases and BCL-2. Some of the cancers that can be treated by use of cannabis flavonoids based on the inhibition of these therapeutic targets include brain, breast, colon, renal, liver, lung, pancreatic, prostate, leukemia, melanoma as well as any other cancers that overexpress the oncogenic factors inhibited by the cannabis flavonoids identified herein.

Abstract: Provided herein are compositions that contain water-soluble vitamin E derivative mixtures (compositions), such as tocopheryl polyethylene glycol succinate (TPGS), TPGS analogs, TPGS homologs and TPGS derivatives. The water-soluble vitamin E mixtures contain mixtures of dimers and monomers of the vitamin E derivative. Provided are products containing the water-soluble vitamin E derivative mixtures, including capsules, soft gel compositions, pre-gel compositions, emulsions and powders.

Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.

Abstract: Provided herein are methods of administering 4-methylpyrazole (4-MP), or physiologically acceptable salts thereof, to subjects of geneic subpopulations expressing specific polymorphisms of the alcohol dehydrogenase and aldehyde dehydrogenase genes. Also provided herein are methods to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol consumption, or reduce the risk of diseases or disorders caused by consumption of ethanol, comprising administering 4-MP, or physiologically acceptable salts thereof, to subjects of these sub-populations.

Abstract: Drugs have been designed and developed with a structural motif allowing local bioavailability in the target organ but that are not broadly distributed at a concentration sufficient to illicit toxic side effects in non-targeted organs. The structural motif subjects the compound to be rapidly metabolized by metabolic enzymes before reaching the non-targeted organs.

Abstract: The present invention pertains to specific clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. It also pertains to the use of this clonidine and/or clonidine derivative for the manufacture of a pharmaceutical composition intended to prevent and/or alleviate the adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. This invention is further directed to a kit comprising: (a) a clonidine and/or clonidine derivative, and (b) at least one alkylating chemotherapeutic agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of cancer.

Abstract: The present invention pertains to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and Clonidine and/or Clonidine derivatives as a sole active ingredient for use in the prevention of skin injury resulting from radiotherapy by transmucocal administration.

Abstract: Provided herein are compounds according to formula (I): Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.

Abstract: There is provided a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of a compound of formula I or a pharmacologically acceptable salt thereof: a combination of said compound of formula I or a pharmaceutically acceptable salt thereof with Brentuximab Vedotin and a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said combination.

Abstract: The present invention generally relates to the use of drugs for the treatment of a neurobehavioral disorder associated with dysfunction of the trimonoamine modulating system (TMMS). More specifically, the invention describes methods for the treatment of a neurobehavioral disorder and/or treatment or prevention of symptoms of a neurobehavioral disorder by administering suitable Isoindole derivatives alone or in combination with other agents so as to provide relatively equal inhibitory effect on serotonin, dopamine and norepinephrine transporters.

Abstract: The present invention provides a transplantation adjuvant for neural progenitor cells containing valproic acid and/or zonisamide as an active ingredient.

Abstract: Disclosed herein are methods for treating or preventing a disease comprising administering a pharmaceutical composition comprising a therapeutically-effective amount of nitazoxanide to a subject having the disease, wherein the disease is causally linked to infection by one or more pathogens selected from the group consisting of members of the genus Ebolavirus, members of the genus Marburgvirus, members of the species dengue virus, human immunodeficiency viruses 1 and 2, and members of the species Mycobacterium tuberculosis.

Abstract: A pramipexole transdermal patch for treatment of neurological disorders including Parkinson's disease that may be administered on a daily basis. The pramipexole transdermal patch of the present invention preferably comprises a drug-containing layer that comprises pramipexole or a pharmaceutically acceptable salt thereof at 2% to about 15% by weight of the dru-containing layer and at least two acrylic polymers wherein each polymer may further comprise carboxyl and/or hydroxyl functional groups. The pramipexole transdermal patch of the present invention may further comprise two or more permeation enhancers with combined pramipexole solubility of great than 50 mg/mL.

Abstract: Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome with gaboxadol or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder.

Abstract: Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.

Abstract: The present application relates to magnesium picolinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable magnesium to mammals and treating or preventing symptoms of magnesium deficiency.

Abstract: The described invention provides stable sustained release particulate formulations of polymorphic Form II of nimodipine and processes for their manufacture that not only can control formation of nimodipine polymorphs, but are practical, consistent from batch to batch, scalable, step-economical and efficient.

Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).